The $14.75-per-share deal will add P2X3 antagonist camlipixant to GSK’s respiratory pipeline, a drug which the UK-headquartered big pharma reckons could be ready for launch in 2026, although it ...

Last year, GSK also added to its respiratory pipe with an agreement to buy Bellus Health for around $2 billion, adding a P2X3 antagonist, camlipixant, in late-stage development as a chronic cough ...

GSK, a leading entity in this space, is optimistic about camlipixant's potential to become a best-in-class treatment option for CRC. Strategic Collaborations and Therapeutic Assessment The ongoing ...